John Oyler
CIK 1042047 · Chief Executive Officer · last filed 2026-08-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
94 SOLARIS AVENUE
CAMANA BAY, GRAND CAYMAN
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONC | Chief Executive Officer | 28,239,116 | $382.27 | $10.79B | -$407.13M | 24 | 2026-08-12 |
| BeOne Medicines Ltd. (BGNE) Delisted | Chief Executive Officer | 10,706,760 | $184.71 | $1.98B | -$407.00M | 63 | 2024-12-17 |
Recent Filings · Page 12 of 12
120 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-11-15 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −150,957 | -$12.15M | EDGAR |
| 2017-10-02 | BeOne Medicines Ltd. (BGNE) Delisted | Grant (A) | +515,000 | $0 | EDGAR |
| 2017-07-10 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −219,400 | -$14.22M | EDGAR |
| 2017-06-26 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −98,500 | -$4.35M | EDGAR |
| 2017-05-01 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −36,149 | -$1.46M | EDGAR |
| 2017-03-20 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −31,989 | -$1.26M | EDGAR |
| 2017-03-06 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −108,999 | -$4.46M | EDGAR |
| 2017-02-21 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −64,963 | -$2.63M | EDGAR |
| 2016-11-18 | BeOne Medicines Ltd. (BGNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-02-09 | BeOne Medicines Ltd. (BGNE) Delisted | Mixed | +9,398,380 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.